Abstract

In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.

Subjects:
Clinical Trials and Observations, Immunobiology and Immunotherapy, Lymphoid Neoplasia
1.
US Food and Drug Administration
.
FDA grants accelerated approval to tafasitamab-cxix for diffuse large B-cell lymphoma. Last updated 3 August 2020
. Accessed 3 February 2023. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma.
2.
Delgado
J
,
Papadouli
I
,
Sarac
SB
, et al.
The European Medicines Agency review of tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma
.
Hemasphere
.
2021
;
5
(
12
):
e666
.
Google Scholar
Crossref
Search ADS
PubMed
 
3.
Salles
G
,
Duell
J
,
González Barca
E
, et al.
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
.
Lancet Oncol
.
2020
;
21
(
7
):
978
-
988
.
Google Scholar
Crossref
Search ADS
PubMed
 
4.
Duell
J
,
Maddocks
KJ
,
González-Barca
E
, et al.
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
.
Haematologica
.
2021
;
106
(
9
):
2417
-
2426
.
Google Scholar
Crossref
Search ADS
PubMed
 
5.
Cheson
BD
,
Ansell
S
,
Schwartz
L
, et al.
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
.
Blood
.
2016
;
128
(
21
):
2489
-
2496
.
Google Scholar
Crossref
Search ADS
PubMed
 
6.
Betensky
RA
.
Measures of follow-up in time-to-event studies: why provide them and what should they be?
.
Clin Trials
.
2015
;
12
(
4
):
403
-
408
.
Google Scholar
Crossref
Search ADS
PubMed
 
7.
Hamadani
M
,
Liao
L
,
Yang
T
,
Chen
L
,
Moskowitz
C
.
Characteristics and clinical outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma who received at least 3 lines of therapies
.
Clin Lymphoma Myeloma Leuk
.
2022
;
22
(
6
):
373
-
381
.
Google Scholar
Crossref
Search ADS
PubMed
 
8.
Crombie
JL
,
Jun
MP
,
Wang
T
, et al.
Real-world outcomes with novel therapies in R/R DLBCL
.
J Clin Oncol
.
2023
;
41
(
16_suppl
):
7552
.
Google Scholar
Crossref
Search ADS
 
9.
Paillassa
J
,
Degoutte
C
,
Oberic
L
, et al.
Tafasitamab lenalidomide in relapsed/refractory large B-cell lymphomas: a multicentric real-world French experience study
.
Hematol Oncol
.
2023
;
41
(
S2
):
591
-
592
.
Google Scholar
Crossref
Search ADS
 
10.
Paul
U
,
Richter
J
,
Stuhlmann-Laiesz
C
, et al.
Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC
.
Leuk Lymphoma
.
2018
;
59
(
5
):
1213
-
1221
.
Google Scholar
Crossref
Search ADS
PubMed
 
11.
Rijal
S
,
Lim
JH
,
Smyth
L
, et al.
The genetic landscape in elderly DLBCL aged > 75 years in the Australasian Leukaemia & Lymphoma Group NHL29 Iric Trial identifies new targetable mutations [abstract]
.
Blood
.
2020
;
136
(
suppl 1
):
18
-
20
.
Google Scholar
 
12.
Jurczak
W
,
Zinzani
PL
,
Hess
G
, et al.
A phase IIa, open-label, multicenter study of single-agent tafasitamab (MOR208), an Fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma: long-term follow-up, final analysis [abstract]
.
Blood
.
2019
;
134
(
suppl 1
):
4078
.
Google Scholar
 
© 2023 by The American Society of Hematology
2023
You do not currently have access to this content.
Sign in via your Institution